The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease
Open accessAbstract
BACKGROUND: The treatment of persistent symptoms attributed to Lyme disease remains controversial. We assessed whether longer-term antibiotic treatment of persistent symptoms attributed to Lyme disease leads to better outcomes than does shorter-term treatment. METHODS: In a randomized, double-blind, placebo-controlled trial conducted in Europe, we assigned patients with persistent symptoms attributed to Lyme disease--either related temporally to proven Lyme disease or accompanied by a positive IgG or IgM immunoblot assay for Borrelia burgdorferi--to receive a 12-week oral course of doxycycline, clarithromycin plus hydroxychloroquine, or placebo. All study groups received open-label intravenous ceftriaxone for 2 weeks before initiating the randomized regimen. The primary outcome measure was health-related quality of life, as assessed by the physical-component summary score of the RAND-36 Health Status Inventory (RAND SF-36) (range, 15 to 61, with higher scores indicating better quality of life), at the end of the treatment period at week 14, after the 2-week course of ceftriaxone and the 12-week course of the randomized study drug or placebo had been completed. RESULTS: Of the 281 patients who underwent randomization, 280 were included in the modified intention-to-treat analysis (86 patients in the doxycycline group, 96 in the clarithromycin-hydroxychloroquine group, and 98 in the placebo group). The SF-36 physical-component summary score did not differ significantly among the three study groups at the end of the treatment period, with mean scores of 35.0 (95% confidence interval [CI], 33.5 to 36.5) in the doxycycline group, 35.6 (95% CI, 34.2 to 37.1) in the clarithromycin-hydroxychloroquine group, and 34.8 (95% CI, 33.4 to 36.2) in the placebo group (P=0.69; a difference of 0.2 [95% CI, -2.4 to 2.8] in the doxycycline group vs. the placebo group and a difference of 0.9 [95% CI, -1.6 to 3.3] in the clarithromycin-hydroxychloroquine group vs. the placebo group); the score also did not differ significantly among the groups at subsequent study visits (P=0.35). In all study groups, the SF-36 physical-component summary score increased significantly from baseline to the end of the treatment period (P<0.001). The rates of adverse events were similar among the study groups. Four serious adverse events thought to be related to drug use occurred during the 2-week open-label ceftriaxone phase, and no serious drug-related adverse event occurred during the 12-week randomized phase. CONCLUSIONS: In patients with persistent symptoms attributed to Lyme disease, longer-term antibiotic treatment did not have additional beneficial effects on health-related quality of life beyond those with shorter-term treatment. (Funded by the Netherlands Organization for Health Research and Development ZonMw; PLEASE ClinicalTrials.gov number, NCT01207739.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wormser, G. P., Dattwyler, R. J., Shapiro, E. D., Halperin, J. J., Steere, A. C., Klempner, M. S., Krause, P. J., Bakken, J. S., Strle, F., Stanek, G., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/508667 · Cited by 2,087
Dimensional assessment of chronic fatigue syndrome
Vercoulen, J. H. M. M., Swanink, C. M. A., Fennis, J. F. M., Galama, J. M. D., van der Meer, J. W. M., & Bleijenberg, G. (1994) · Journal of Psychosomatic Research · doi:10.1016/0022-3999(94)90099-x · Cited by 1,306
Klempner, M. S., Hu, L. T., Evans, J., Schmid, C. H., Johnson, G. M., Trevino, R. P., Norton, D., Levy, L., Wall, D., McCall, J., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107123450202 · Cited by 758
EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis
Mygland, Å., Ljøstad, U., Fingerle, V., Rupprecht, T., Schmutzhard, E., & Steiner, I. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02862.x · Cited by 749
A simple sample size formula for analysis of covariance in randomized clinical trials
Borm, G. F., Fransen, J., & Lemmens, W. A. J. G. (2007) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.02.006 · Cited by 575
van Dam, A. P., Kuiper, H., Vos, K., Widjojokusumo, A., de Jongh, B. M., Spanjaard, L., Ramselaar, A. C. P., Kramer, M. D., & Dankert, J. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.4.708 · Cited by 573
Study and treatment of post Lyme disease (STOP-LD): A randomized double masked clinical trial
Krupp, L. B., Hyman, L. G., Grimson, R., Coyle, P. K., Melville, P., Ahnn, S., Dattwyler, R., & Chandler, B. (2003) · Neurology · doi:10.1212/01.wnl.0000071227.23769.9e · Cited by 419
A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy
Fallon, B. A., Keilp, J. G., Corbera, K. M., Petkova, E., Britton, C. B., Dwyer, E., Slavov, I., Cheng, J., Dobkin, J., Nelson, D. R., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000284604.61160.2d · Cited by 389
Raoult, D., Houpikian, P., Dupont, H. T., Riss, J. M., Arditi-Djiane, J., & Brouqui, P. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.2.167 · Cited by 352
Wormser, G. P., Dattwyler, R. J., Shapiro, E. D., HALPERIN, J. J., Steere, A. C., Klempner, M. S., Krause, P. J., Bakken, J., Strle, F., Stanek, G., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/522848 · Cited by 302
Cited by
Steere, A. C., Strle, F., Wormser, G. P., Hu, L. T., Branda, J. A., Hovius, J. W. R., Li, X., & Mead, P. S. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.90 · Cited by 845
ACVIM consensus update on Lyme borreliosis in dogs and cats
Littman, M. P., Gerber, B., Goldstein, R. E., Labato, M. A., Lappin, M. R., & Moore, G. E. (2018) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.15085 · Cited by 152
Metadata
- Authors
- Berende, A., ter Hofstede, H. J. M., Vos, F. J., van Middendorp, H., Vogelaar, M. L., Tromp, M., van den Hoogen, F. H., Donders, A. R. T., Evers, A. W. M., & Kullberg, B. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-03-31
- Volume
- 374
- Issue
- 13
- Pages
- 1209-1220
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2318919763
- Cited by
- 261
- References
- 23
- FWCI
- 32.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease. https://app.cochat.ai/papers/10.1056/nejmoa1505425
- The paper
- Berende, A., ter Hofstede, H. J. M., Vos, F. J., van Middendorp, H., Vogelaar, M. L., Tromp, M., van den Hoogen, F. H., Donders, A. R. T., Evers, A. W. M., & Kullberg, B. J. (2016). Randomized Trial of Longer-Term Therapy for Symptoms Attributed to Lyme Disease. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1505425
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.